More Insulin Biosimilars Are Forthcoming; The Market Outlook for Them
During the past few weeks, in both SEC-mandated (for publicly-held companies) earnings reports and investor presentations, plus in the business news and pharmaceutical industry trade press, we received several important, relevant updates on not one, but on FOUR insulin biosimilars currently in development from two different companies. We also know that in addition to them, insulin biosimilars are in development from at least three additional companies, plus as the " innovators " , the traditional " Big Three " insulin-makers of Lilly, Novo Nordisk and Sanofi continue making their bestsellers (for the time being, anyway).&n...
Source: Scott's Web Log - September 12, 2022 Category: Endocrinology Tags: 2022 Biosimilar Biosomilars generic insulin Source Type: blogs
Updated Medicare and Medicaid Drug Spending Data Released
On November 15, 2016, the Centers for Medicare and Medicaid Services (CMS) released updated Medicare and Medicaid drug spending data, to include information for calendar year (CY) 2015 through its online interactive dashboards for Medicare and Medicaid. The inclusion of the Medicaid drug spending data on the public dashboard is new this year, as is the addition of high-level (aggregated) Medicare drug rebate data.
CMS noted that “there is significant growth in spending on prescription drugs, representing a significant burden.” In CY 2015, total prescription drug costs amounted to roughly $457 billion – an estimated ...
Source: Policy and Medicine - December 14, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Like I said: Advair Diskus too hard to copy
Generics maker Teva confirmed it doesn’t expect to bring a generic version of Advair to market before 2018, even though patents are expiring sooner. The reason for the delay: the inhaler device is too hard to replicate.
As I wrote last month (How a tough manufacturing process for Advair might help GSK):
Unlike the typical round, white pill, its complex inhaler mechanism was never designed to be produced in huge quantities in multiple locations around the world, where different environmental conditions and variations in raw materials could make it hard to duplicate. So manufacturing has been a challenge for GSK and co...
Source: Health Business Blog - October 10, 2013 Category: Health Managers Authors: dewe67 Tags: Pharma Advair Source Type: blogs
How a tough manufacturing process for Advair might help GSK
When GSK introduced its Advair Diskus to the market about 15 years ago, it wasn’t expected to be such a big hit, never mind reaching close to $8 billion in sales as it did last year. It’s actually not so abnormal for demand for new drugs to be way off their initial projections and it’s typically no big deal. If a drug is unexpectedly popular it may take a while for production to ramp up but then the problem is usually over.
But Advair is a different beast. Unlike the typical round, white pill, its complex inhaler mechanism was never designed to be produced in huge quantities in multiple locations around t...
Source: Health Business Blog - September 16, 2013 Category: Health Managers Authors: dewe67 Tags: Devices Pharma Source Type: blogs
